Arwed A Burrichter is a registered European and German patent attorney. He prosecutes and litigates European patents and provides strategic advice on patents and supplementary protection certificates (SPCs) in the fields of pharmaceuticals, biochemistry, organic chemistry and polymer chemistry.
Dr Burrichter has frequently served as lead patent counsel in various important pan-European pharmaceutical and chemistry-related cases. As such, he has a substantial track record in European Patent Office (EPO) opposition and national nullity proceedings.
Besides his litigation and EPO opposition work, Dr Burrichter maintains an extensive patent prosecution docket for his clients.
Dr Burrichter is known for his perceptive counselling of US clients, which frequently rely on his advice for important strategic decisions in European patent prosecution and litigation matters. He developed an affinity for the United States and a keen sense of the particularities associated with the US legal system through more than five combined years of scientific and professional experience there, including a period as a foreign associate at Ropes & Gray LLP, New York (formerly Fish & Neave LLP).
Dr Burrichter’s capacity for advocating and devising effective winning strategies makes him one of the most sought-after chemistry patent counsel in Germany. He has been consistently recognised in JUVE’s patent category as one of Germany’s most frequently recommended patent attorneys for chemistry-related matters.
A frequent author and speaker, Dr Burrichter has recently addressed topics such as the upcoming Unified Patent Court, reform of the German patent nullification trial system and pharma patent term extensions via SPCs.
Dr Burrichter studied organic chemistry at the University of Bonn, Germany and obtained his PhD from the University of Southern California, Los Angeles, working on hydrocarbon chemistry under the guidance of Nobel laureate George A Olah.
COHAUSZ & FLORACK
Patent- und Rechtsanwälte
Sprycel – new plausibility threshold for life sciences patents?
IAM Life Sciences 2018
The Technical Board of Appeal of the European Patent Office (EPO) decision (February 1 2017) upholding the revocation of Bristol-Myer Squibb’s (BMS) European Patent 1169038 for lack of inventive step came as a shock and a surprise for many in the pharmaceutical sector.
Using the UPC to your benefit in pharmaceuticals and life sciences
IAM Life Sciences 2016
Proposed structure of the Unified Patent Court
Patents in Europe 2016/17: Helping business compete in the global economy
Cross-border patent litigation in Europe: change is coming
IAM Life Sciences 2015
Federal court stakes new ground for reach-through claims
Intellectual Asset Management Magazine
Reach-through claims – which allow broad protection for an invention – have been a contentious issue for years. The German Federal Court’s recent decision on dipeptidyl-peptidase inhibitors suggests that the matter is far from settled
The must-know facts about patent term extensions in Europe
Patents in Europe
Patent term extensions are key tools for the protection of drugs in Europe. Understanding their complex legal framework is just as crucial
Key issues in building a strong life sciences patent portfolio
Senior executives in the life sciences industries need a keen understanding of how to build and maintain a strong portfolio in order to enforce and defend their IP rights. Well-managed IP rights will also be an enabler of collaboration and further innovation
Patenting biotechnology inventions via the EPO
Patents in Europe 2011/2012
By patenting a biotechnological invention via the European Patent Office, a patent owner can ensure the protection of its patent across Europe
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email